cAMP-specific 3',5'-cyclic phosphodiesterase 4D isoform 2 (PDE4D2) (PDE4D2)

PDE4D2 is a short isoform of the cAMP-specific 3',5'-cyclic phosphodiesterase 4D (PDE4D) enzyme, which plays a pivotal role in the regulation of intracellular cyclic adenosine monophosphate (cAMP) levels (UniProt, NIH [1.5.2]). Unlike the long isoforms of PDE4D, PDE4D2 lacks the Upstream Conserved Region 1 (UCR1) and exists primarily as a monomer, which influences its regulatory properties and subcellular localization (NIH [1.2.4, 1.5.4]). It is responsible for the hydrolysis of cAMP into 5'-AMP, thereby terminating cAMP-mediated signaling pathways such as those involving protein kinase A (PKA) and the cAMP-response element-binding protein (CREB) (NIH [1.2.2, 1.3.1]). PDE4D2 is particularly significant in the context of neuroinflammation and cognitive function, as its expression is often induced by chronic cAMP elevation as part of a negative feedback loop (NIH [1.1.1, 1.2.3]). In disease states, PDE4D2 has been implicated in the progression of neurodegenerative disorders like Alzheimer's disease and has been shown to promote cancer cell proliferation in various solid tumors (NIH [1.3.5, 1.5.3]). Therapeutic targeting of PDE4D2 with selective inhibitors is an active area of research, aiming to enhance cognitive performance and provide anti-inflammatory effects while potentially reducing the emetic side effects associated with non-selective PDE4 inhibitors (NIH [1.3.1, 1.3.2]). Interacting drugs include pan-PDE4 inhibitors like roflumilast and apremilast, as well as more selective candidates like zatolmilast (BPN14770) (NIH [1.3.1, 1.3.2]).

Other names

Phosphodiesterase 4D2PDE4D isoform 2cAMP-specific 3',5'-cyclic phosphodiesterase 4D2DPDE3HSPDE4D1

Inhibition of cAMP-specific phosphodiesterase activity, which prevents the hydrolysis of cAMP to 5'-AMP, thereby increasing intracellular cAMP levels and activating downstream effectors like PKA and CREB (NIH [1.2.2, 1.3.1]).